n November we’ve been present at two important conferences in the USA and England. Furthermore, we’ve been meeting our distribution partner from Saudi Arabia both in the Netherlands and in Saudi Arabia.
- SAWC Fall – November 2-5, Las Vegas, USA.
The Symposium on Advanced Wound Care (SAWC) typically covers a wide range of topics related to wound healing, including new research, clinical practices, and innovations in wound care. This conference brings together healthcare professionals, researchers, and industry experts to discuss and share knowledge in the field of wound care. DEBx Medical was present at SAWC Fall to to gain valuable insights into the local market and assess its current status. Our presence allowed us to engage with industry experts, explore emerging trends, and deepen our understanding of the market dynamics for informed decision-making.
- Wounds UK 2023 – November 6-8, Harrogate, UK – Edge Medical. This conference was organized and attended by both DEBx Medical and Edge Medical.
In collaboration with our distributor Edge Medical, DEBx Medical was present during the largest UK 3-day conference in Harrogate. This was the third time that we participated in this event together with our distribution partner.
There was a clear difference this year compared to previous years. While in previous years we were really introducing our product and people mainly came to our stand because they were curious about ‘the new faces’ at the conference, we now saw that the Edge Medical team has been working hard to to create awareness. Many clinicians, mainly Tissue Viability Nurses, came to our stand as ‘acquaintances’ of the team and to talk about their recent experiences. Now with full reimbursement via Drug Tariff from January next, this bodes well for the further development of the market.
- Sarabeel Commercial Co. – WK 46-47, Strategy Meetings in Amsterdam, Jeddah and Riyadh.
In the last week of November, our CEO Bert Quint visited Saudi Arabia. Here he met with our distributor, Sarabeel Commercial Co, to discuss a strategic partnership for the Middle East. Sarabeel will play a key role in ensuring wider accessibility and impact across the region in distributing DEBRICHEM. In a short period of time, Sarabeel has already introduced our product in over 30 hospitals targeting over 100 clinicians.
Next to meeting Sarabeel, Bert Quint had a meeting with our investor TVM to discuss establishing a regional headquarters in Saudia Arabia, which is part of the investment agreement signed in August 2023. The decision to establish a headquarters in the Middle East marks a significant milestone in our journey to achieve Global expansion. We want to be close to our markets, and this one will serve more than half a billion people.
